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Joanna Chataway, Rebecca Hanlin, Lois Muraguri and Watu Wamae 
 
 
PDPs as social technology innovators in global health:   
Operating Above and Below the Radar. 
 
3 main messages 
 
• PDPS constitute social technology innovations which promote, develop 
and aim to distribute physical technologies to those who need them and 
they need to be evaluated on this basis;  
 
• More attention needs to be paid to PDP’s organisation and management.  
Incorporating  this type of analysis into evaluation may reinforce 
engagement in types of collaboration important to health systems 
development and strengthening; 
 
• PDPs can use their distinctiveness to capture and use ‘Below the Radar’ 
networks and knowledge to further develop social and physical 
technologies in the interests of global health.  
 
 
Abstract 
 
 
PDP success rests on an ability to create new science and technology but it also 
depends on the creation of new organisational structures and cultures which can 
successfully develop appropriate technology and products and get them to those who 
need them.  One of the main reasons PDPs are supported and funded is that they 
constitute a ‘social technology’ innovation.  As such they work both with ‘above the 
radar’ established and formal mechanisms for developing new products and with 
‘below the radar’ networks, organisations and physical technologies in developing 
countries so that products are appropriate, understood and accepted and can be 
made accessible to those who need them.   We argue that thinking about PDPs in 
this light provides a useful framework for evaluation.  
 
Introduction 
 
Global product development partnerships are often characterised as ‘technology 
push’ initiatives aimed at providing new science and technology based products for 
neglected diseases applying the best science and technology to meet global health 
needs.  Yet this characterisation is only a partial description of many PDPs.  It is also 
possible to view PDPs themselves as innovations developing novel networks, new 
ways of dividing labour and relevant management and organisational skills to serve 
global health objectives.  Looking at PDPs in this light, we can see them as social 
technology innovations designed to develop and distribute physical technologies in 
the shape of new products and drugs.  
 
PDPs develop new medicines or medical equipment for people in developing 
countries who lack the economic resource and political clout to demand and access 
effective products.   Yet it is now well established that new technologies and products 
alone are not enough.  Highly complex manufacturing and access problems need 
also to be resolved.  This set of issues is difficult in large part because the answers 
are not standard.  Whereas an AIDS vaccine may have in theory widespread global 
  
 
 
or regional applications, distributional and access issues involve numerous local 
factors which need addressing.  Moreover, for technologies and products to be 
successful they must be appropriate to local conditions and need to be demanded 
locally.  Local demand involves not only appreciation for the product but also for the 
means of distribution.  Thus, PDPs need to engage with and contribute to local 
organisations, institutions and individuals which have and are building political voice.  
It is PDPs’ ability to combine product development with this targeted and efficient 
approach to working locally in developing countries with health, community and 
development organisations which makes them distinctive. 
 
 
Section 1.   PDPs as social technologies 
 
Richard Nelson defines social technologies by using an analogy to the limitations of 
written recipes for food preparation: 
 
…a recipe characterisation of what needs to be done represses the fact that many 
economic activities involve multiple actors, and require some kind of a coordinating 
mechanism to assure that the various aspects of the recipe are performed in the 
relationships to each other needed to make the recipe work.  The standard notion of 
a recipe is mute about how this is to be done…. [We] propose that it might be useful 
to call the recipe aspect of an activity its “physical” technology, and the way work is 
divided and coordinated its “social” technology (Nelson, 2008:11) 
 
During the 1990s it was widely perceived that neither the public, nor private nor NGO 
sectors alone could develop new technologies and make them accessible to the 
world’s poor who needed them.  The hope was that the imbalance in spending on 
health R&D, in favour of the world’s wealthy, could be partially rectified via the 
creation of new organisations which would bring a range of actors together to work 
effectively around specific disease and health agendas.  Whilst the recipes for doing 
this may have been understood (bringing together the power of public and private 
sectors in technological innovation and the private and NGO sectors in distribution) 
creating and  managing the organisations that could divide and manage the work 
was an entirely different matter.  We are only now beginning to see analysis of the 
different organisational forms operating under the PDP umbrella and the various 
modes of working that resulted in the effort to create social technologies for 
neglected disease. 
 
Using the concept of social technologies highlights a number of shortcomings in 
other ways of looking at the intractable issues involved in addressing neglected 
diseases.  One powerful strand of argument for instance views the problem as one of 
incentives and investment. According to this argument if enough money is pumped 
into the area of neglected diseases and if the right incentives are created, the 
problem will be solved.  In a previous Global Forum for Health Research Review, 
Orsenigo et al make clear the limitations of this approach (Orsenigo, 2008).  Using 
the example of IAVI Orsenigo et al argue that PDPs are both innovation integrators, 
providing a hub for science and technology development and brokers amongst the 
plethora of health and development stakeholders needed to put potential product 
candidates through clinical trials and to ensure widespread access should a safe and 
efficient product be the outcome.  Thus PDPs go well beyond classic measures for 
addressing ‘market failure’. They are necessary attempts to address ‘social 
technology failure’. This argument is developed in further articles which provide more 
detail about the way in which IAVI fashions itself in both roles (Chataway et al 2007, 
Chataway et al 2009). 
 
  
 
 
 
It is the combination of these two sets of activities around concrete product 
development agendas which is, in part at least, why PDPs have attracted widespread 
support and have secured financial resource; PDPs bring together a range of actors 
in public, private and NGO sectors with a targeted mission of introducing, developing 
and making accessible new technologies and treatments to those who need them in 
poor countries.  Their efforts have had to include support for new science, technology 
and product development and a range of brokering and capacity building activities 
around defined product development activities including clinical trials.   
 
This is PDP’s social technology innovation and this is why PDPs are widely 
considered appropriate vehicles for the development new physical technologies.  
Other public, private and charity organisations can undertake activities in discrete bits 
of the value chain and have specific capabilities but PDPs introduced a coherent 
organisational, management and cultural approach to bringing together innovation 
and development under one organisational banner in a targeted way that moved 
things forward more rapidly than the alternatives (Moran et al, 2005). 
 
PDPs may share characteristics but they are not of course identical.  For example 
IAVI and the Malaria Vaccine Initiative (MVI) are similar in overall goal and mission: 
both are PDPs aiming to develop and make accessible to poor people in developing 
countries vaccines for major neglected diseases.  Both have been based around 
clinical trials. However, their social technology histories differ and IAVI and MVI 
behave differently in their integrator and broker roles.  These social technology 
differences are becoming more accentuated as their respective success in 
developing new physical technologies becomes more apparent. 
 
In some respects IAVI and MVI seem to be moving in opposite directions with IAVI 
moving in a more ‘integrator’ fashion – increasingly becoming identified with  
particular scientific approaches (rather than a very broad umbrella) and increasing 
commitments to basic science in the US and Europe.  In MVI on the other hand we 
see a move towards addressing delivery issues and health systems strengthening 
(development and broker issues) and working more closely with a variety of UN, 
multilateral and bilateral agencies. In some senses IAVI maintains its virtual pharma 
company identity and MVI is moving away from thati.  
 
The reasons for this divergence include the stage of scientific progress. The scientific 
challenges effecting both AIDS and malaria vaccine research are immense but at 
present malaria vaccine researchers have been able to make more headway than 
AIDS vaccine researchers.  Second each organisation has evolved a different history 
or ‘institutional logic’ (DiMaggio, 1997) whereby different norms, values and cultures 
vie for attention and come to dominate.  The implication is that there are different 
ways IAVI and MVI could take to approach the problems affecting the science and 
reaching its intended goal; there is not one way of successfully engaging in vaccine 
development for infectious diseases such as AIDS and malaria and outcomes in 
decisions about how to tackle problems are influenced by technical factors but also 
by a organisation’s history, structure and culture. 
 
 
Section 2.  Using PDP social technology for better outcomes and Below the 
Radar Innovation 
 
An analogous and useful way of looking at the roles of PDPs can be taken from work 
by Gardner et al who argue that improving access to essential products and services 
requires three forms of innovation: technological, social and adaptiveii.  Adaptive 
  
 
 
means “involving both providers and communities to contextualise the adoption of 
goods and services to local settings” (Gardner et al, 2007).   
 
It is now well established that successful innovation is in most cases ‘non-linear’ that 
it often involves numerous interactions between consumers and users (and of course 
patients).  Adaptation then is not a passive phenomenon but often requires active 
interaction and communication between those who produce and those who use 
products and technologiesiii.  This adaptation can be around modification of physical 
technology (feedback and knowledge from local consumers which help improve the 
recipe) or in social technology (new ways of dividing and conducting work which can 
facilitate the development and the distribution of technologies).  
 
Many PDPs, including MVI and IAVI are in a good position to learn about local 
contexts and innovate in the area of social technologies on the basis of local 
knowledge.  This social technology will be invaluable in devising plans for the 
production, distribution, acceptance and use of new treatments and drugs.  It is clear 
from many studies that have been carried out that vaccines and other drugs are 
rejected because not enough resource is devoted to understanding local contexts 
(Leach and Fairhead 2007). Moreover, the structure of local distribution channels 
impacts significantly on the way drugs and treatments are consumed (Mackintosh 
and Mujinja, 2008).  Thus, by using their connections and networks which span local 
contexts and global product development, PDPs can hopefully give rise to social 
technology innovations which will contribute to making new products and 
technologies more accessible.  By using their existing social technology innovation 
(existing networks and new working partnerships) to generate further useful social 
technologies. 
 
PDPs can also use their distinctive networks, ethos and orientation to input into 
physical technology development.  As mentioned previously it is now widely accepted 
that most innovation is relatively non-linear with many feedback loops between 
different stages of product development.  Most companies now innovate on the basis 
of this analysis and have ongoing communication with their users and consumers.  
They know their customer base and innovate accordingly.   
 
Although the feedback loops are perhaps less in some areas of drug development, it 
is certainly true that most large companies orient their new product development 
activities towards the world’s wealthier customers in high or middle income 
companies.  Drugs and treatment regimes are oriented towards those markets.  
There are less likely to know about or be interested in the range of treatments or 
medical practices used in poorer countries and by poorer people.  This of course was 
one of the factors behind the creation of PDPs.  There is scope for PDPs to use their 
different connections, networks and social technologies to generate new science, 
technology and products.  Although this may sound to some to be naïve wishful 
thinking, the artemisinin story or the science around sex workers and others who 
have high level resistance to HIV are examples of the potential of this approach.   
 
We have labelled this more user led innovation process involving poorer consumers 
in developing countries, below the radar innovation (BRI).  Below the radar because 
the potential for productive innovation for poor users and consumers is not generally 
of interest to large Western companiesiv and is therefore not a major focus for 
product development activity.  Large western companies are unlikely to be interested 
in working to adapt products on the basis of feedback from poor consumers and 
areas of product and service activity related to poor people’s needs remain below the 
radar.  PDPs and companies from other developing countries may be able to 
progress this type of innovation in much more direct ways.  BRI can be found in a 
  
 
 
range of sectors but is of particular relevance in health, agriculture and energy as 
these are key sectors for poor people. 
 
Feedback and adaptation requires competence and capability building.  PDPs 
themselves have to acquire the capabilities which will let them absorb local 
knowledge.  When working in poorer developing countries they will often also need to 
contribute to local capacities and capabilities.  A number of PDPs have impressive 
records in building new scientific, technological and management capacity in 
developing countries (Chataway et al, 2007 and Chataway et al, 2009).   
 
 
Conclusion: Evaluating PDPs as social technology innovators 
 
Clearly the mission of most PDPs is to develop appropriate new technologies and 
products for global health.  All activities need to be judged in relation to this mission. 
Yet narrow metrics looking at outputs may miss some of the real contributions that 
PDPs make.  They may also provide perverse incentives for autonomous styles of 
operation when collaborative approaches may be far more suitable particularly in 
light of recent concerns about health systems strengthening. 
 
If PDPs are viewed as social technology innovations and if, as we have argued, this 
is their raison d’etre, they should be evaluated on the basis of their contributions to a 
variety of activities involved in developing new products and making them accessible 
to poor people in developing countries.     Outcomes rather than strictly output based 
assessments of overall contribution might evaluate whether PDPS have positively 
changed the behaviour of a range of groups, individuals, organisations and 
institutions involved in complex interactions around getting better medicines to poor 
people in developing countries.  For example assessment of how activities such as 
capacity building or advocacy activities has contributed or is likely to contribute to 
better outcomes for target groups’ access to medicines needs to be evaluated.   In 
turn this type of evaluation may contribute to health systems strengthening objectives 
by contributing parties involved in global health to view their activities as part of a 
complex whole. 
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i
   Whilst there is truth in these broad characterisations there is also a good deal more 
subtlety in a more detailed account of the strategies that both organisations are 
pursuing. 
 
 
ii
  Technological and social innovation are used in the sense of creating new products 
and processes on the one hand ensuring access on the other hand.    
 
 
iii
  A recent article in The Economist  about’frugal innovators’ provides excellent 
examples of adaptive innovation in the Indian health service. 
 
 
iv
   However, as Christenson (1997) has pointed out highly successful and disruptive 
(in the sense that it disrupts existing supply and value chains) innovation often has its 
roots in low income markets.  In some sense the rise of the Indian pharmaceutical 
industry can be seen as an example of this as Indian companies have their roots in 
developing generic drugs for poor users. 
 
 
 
 
 
  
 
 
                                                                                                                                            
 
 
 
